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IMPORTANCE Expansion of donor acceptance criteria for liver transplant increased the risk for
early allograft failure (EAF), and although EAF prediction is pivotal to optimize transplant
outcomes, there is no consensus on specific EAF indicators or timing to evaluate EAF.
Recently, the Liver Graft Assessment Following Transplantation (L-GrAFT) algorithm, based
on aspartate transaminase, bilirubin, platelet, and international normalized ratio kinetics, was
developed from a single-center database gathered from 2002 to 2015.
OBJECTIVE To develop and validate a simplified comprehensive model estimating at day 10
after liver transplant the EAF risk at day 90 (the Early Allograft Failure Simplified Estimation
[EASE] score) and, secondarily, to identify early those patients with unsustainable EAF risk
who are suitable for retransplant.
DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study was designed to develop a
score capturing a continuum from normal graft function to nonfunction after transplant. Both
parenchymal and vascular factors, which provide an indication to list for retransplant, were
included among the EAF determinants. The L-GrAFT kinetic approach was adopted and
modified with fewer data entries and novel variables. The population included 1609 patients
in Italy for the derivation set and 538 patients in the UK for the validation set; all were
patients who underwent transplant in 2016 and 2017.
MAIN OUTCOMES AND MEASURES Early allograft failure was defined as graft failure (codified
by retransplant or death) for any reason within 90 days after transplant.
RESULTS At day 90 after transplant, the incidence of EAF was 110 of 1609 patients (6.8%) in
the derivation set and 41 of 538 patients (7.6%) in the external validation set. Median
(interquartile range) ages were 57 (51-62) years in the derivation data set and 56 (49-62)
years in the validation data set. The EASE score was developed through 17 entries derived
from 8 variables, including the Model for End-stage Liver Disease score, blood transfusion,
early thrombosis of hepatic vessels, and kinetic parameters of transaminases, platelet count,
and bilirubin. Donor parameters (age, donation after cardiac death, and machine perfusion)
were not associated with EAF risk. Results were adjusted for transplant center volume. In
receiver operating characteristic curve analyses, the EASE score outperformed L-GrAFT,
Model for Early Allograft Function, Early Allograft Dysfunction, Eurotransplant Donor Risk
Index, donor age × Model for End-stage Liver Disease, and Donor Risk Index scores,
estimating day 90 EAF in 87% (95% CI, 83%-91%) of cases in both the derivation data set
and the internal validation data set. Patients could be stratified in 5 classes, with those in the
highest class exhibiting unsustainable EAF risk.
CONCLUSIONS AND RELEVANCE This study found that the developed EASE score reliably
estimated EAF risk. Knowledge of contributing factors may help clinicians to mitigate risk
factors and guide them through the challenging clinical decision to allocate patients to early
liver retransplant. The EASE score may be used in translational research across
transplant centers.
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E arly allograft failure (EAF) is a major determinant of out-come after liver transplant (LT).1-6 Concerns have beenraised on the acceptance of increased-risk donors (eg,
elderly, highly comorbid, steatotic, donors after circulatory
death [DCD]). The acceptance of individuals with such condi-
tions might offset other w ise achieved sur v ival
improvements.7-10 In addition, the introduction of machine
perfusion (MP) has led to the acceptance of grafts at higher risk
of failure.11-15
The wide range of definitions as early allograft
dysfunction,3,5,16,17 primary dysfunction,1,18 initial poor graft
function,1 posttransplant failure,6 primary nonfunction,1 and
delayed nonfunction19 all rely on 2 mutually exclusive alter-
natives: recovery or failure. The lack of agreement on true in-
dicators and timing for evaluating EAF hampered a shared EAF
definition. Recently, 2 studies17,20 have highlighted that the re-
covery after LT is a continuous process punctuated by vari-
ous events, which may change the prognosis with cascading
detrimental effects. However, day 90 has been acknowl-
edged as a reliable time to assess failure-free survival.6,17,20
Early allograft failure is the result of a complex interplay
between donor- and procurement-related factors in combina-
tion with perioperative factors, which all contribute to deter-
mine the severity of ischemia-reperfusion injury.18,21,22 Early
allograft failure may be precipitated by clinical events (eg, graft
rejection, drug toxicity, kidney failure, thrombosis of hepatic
vessels [THV], or sepsis) that may be negatively associated with
patient survival. Timely prediction of EAF is pivotal to iden-
tify patients potentially benefiting from a rescue retransplant
before severe complications develop and preclude this
option.23,24 When massive cytolysis and signs of liver failure
occur within the first 10 days after LT, the indication for re-
transplant is evident, independent from evidence of THV. Nev-
ertheless, after this first 10 days, the decision of whether or
not to retransplant is frequently challenging.
The indicators of EAF have changed over time from ami-
notransferase peaks1,2 to metabolic factors3,16,17 and more re-
cently to a combination of time-dependent kinetic param-
eters, including aspartate aminotransferase (AST) level,
bilirubin level, international normalized ratio, and platelet
count. According to this approach, the Liver Graft Assess-
ment Following Transplantation (L-GrAFT) model, a 40-data-
entry algorithm based on a 2002 to 2015 cohort from a large-
volume North American center, was developed.20 However,
it has not been validated in external multicenter databases.
Our primary study objective was to develop and validate
a simplified but comprehensive model available at day 10 af-
ter LT to estimate the risk of EAF. The secondary objective was
to identify cases at the highest risk of failure to guide the de-
cision-making process for early retransplant.
Methods
Study Design
This is a retrospective multicenter study carried out on pro-
spectively maintained databases identifying adult patients who
were submitted to deceased donor LT. First, the L-GrAFT model
was validated using an Italian database. Using an L-GrAFT–
like method, a novel Early Allograft Failure Simplified Esti-
mation (EASE) score was developed and then internally vali-
dated. Afterward, the EASE score was validated using an
external UK data set (validation set). A detailed description of
EASE model development is provided in the eMethods in the
Supplement. This study followed the Strengthening the Re-
porting of Observational Studies in Epidemiology (STROBE)
reporting guideline25 and is registered at ClinicalTrials.gov
(NCT03858088).26 The institutional review board of Policlinico
Universitario A. Gemelli IRCCS (coordinating center) approved
the study. This board also waived the requirement for obtaining
patient consent owing to the retrospective study design.
Setting
Participants included 14 Italian and 2 UK transplant centers
with high (≥70 transplants per year) and intermediate (36-69
transplants per year) activity volume,27,28 with a high- to in-
termediate-volume ratio of 1:1 in derivation and validation sets.
Population
Both the derivation and validation data sets included consecu-
tive adult patients who had undergone a transplant in 2016 and
2017. Median (interquartile range) ages were 57 (51-62) years
in the derivation data set and 56 (49-62) years in the valida-
tion data set. Patients with acute liver failure, HIV, or com-
bined, domino, or living donor grafts were excluded.
Variables and Data Collection
Data collected to develop the EASE score included the follow-
ing: (1) recipient demographic characteristics (age, sex, and
body mass index), primary end-stage liver disease diagnosis,
diabetes, wait time, perioperative laboratory results (Model for
End-stage Liver Disease [MELD] score at transplant and post-
operative day [POD] 1 to 10 AST level, bilirubin level, and plate-
let count), pretransplant dialysis or mechanical ventilation,
packed red blood cell (PRBC) transfusions at LT, and condi-
tions complicating the postoperative course (ie, vascular
thrombosis, sepsis, multiorgan failure, other complications,
Key Points
Question Can the individual risk estimation for early allograft
failure (EAF) be improved in view of liver retransplant?
Findings In this multicenter cohort study investigating the
association between donor-recipient factors and EAF, a novel Early
Allograft Failure Simplified Estimation (EASE) score was
developed. The score includes Model for End-stage Liver Disease
score, transfused packed red blood cells, and hepatic vessel early
thrombosis as well as transaminases, platelet, and bilirubin
kinetics as variables on day 10 after transplant. The EASE score
outperformed previous model scores, estimating EAF risk with
87% accuracy on day 90 after transplant; EASE was developed on
a multicenter Italian database (1609 recipients) and validated on
an external UK database (538 recipients).
Meaning In this study, the EASE score rated the EAF risk
(0%-100%) and identified cases at unsustainable risk to be listed
for retransplant.
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and length of stay); (2) donor demographic characteristics (age
and sex); (3) grafts (DCD, donation after brain death [DBD], MP
grafts, and macrosteatosis); and (4) surgical procedure char-
acteristics (split, cold ischemia time, warm ischemia time, ve-
novenous bypass, temporary portocaval anastomosis, and in-
traoperative packing). Data were collected daily in electronic
databases by data managers at each center. The area under the
curve (AUC) and the rate of change or trend (slope) for AST lev-
els, platelet counts, and bilirubin levels during the first 10 PODs
were the calculated variables. For each patient, the AUCs and
slopes as well as the AUC square form were recorded.
Outcome Definition
Early allograft failure was defined as graft failure (need for re-
transplant or death) for any reason at POD 90.20 This defini-
tion also captures cases of late-occurring EAF (delayed
nonfunction).19 We considered as EAF determinants all events
potentially leading to EAF, independently if they were or were
not strictly associated with ischemia-reperfusion injury. In-
deed, vascular (thrombosis of the hepatic artery or portal vein),
biliary, toxic, and major hemodynamic events were included
because any of them interacting with parenchymal dysfunc-
tion can affect graft function recovery and favor graft failure
and death. Events potentially leading to EAF were recorded.
The risk of failure was stratified as 5 classes. The highest-
risk class was defined as unsustainable, consistent with pre-
vious literature,29 and the cutoff between classes 4 and 5 was
defined as the unsustainable risk cutoff.
Criteria leading to retransplant were based on clinical judg-
ment and included (1) evidence of biochemical signs of a non-
functioning graft; (2) expected deterioration of other vital func-
tions leading to death; and (3) expected substantial change of
prognosis after the second graft.
Statistical Analysis
To build a comprehensive model, we considered an exten-
sive set of preoperative and intraoperative variables. Owing to
the time-dependent incidence of EAF, the potential determi-
nants associated with graft failure were investigated at differ-
ent time intervals (PODs, 2-15, 2-30, 2-60, and 2-90) using uni-
variate Cox regression analysis according to the L-GrAFT
method.20 Logistic regression analysis was then used. The
backward stepwise procedure for variable selection was ini-
tially adopted. Variables were then tested using a nonauto-
matic approach. The discrimination ability of the final model
was investigated using the receiver operating characteristic
(ROC) curve method. The discrimination ability was also con-
firmed through internal validation using bootstrap resamp-
ling and through external validation using the UK data set. Two
hundred bootstrapped samples were taken with replacement
from the original data set, with each bootstrapped sample con-
taining 1000 cases. The goodness of fit of the new score was
assessed using the Hosmer-Lemeshow test. The calibration of
the final model in the derivation and external validation sets
was evaluated using the calibration-BELT method. Details are
reported in eFigure 4 in the Supplement.
We initially tested β coefficients of the L-GrAFT model de-
rived from 40 data entries, validating the model. Then, we re-
duced the number of entries by recording only data at speci-
fied PODs.
Four subsequent logistic models (1-4) were developed in
the derivation set to reduce the number of data entries, im-
proving the Harrell C statistic and including additional fac-
tors. Five additional models (5-9) were tested to investigate the
impact of THV and of DCD and MP grafts. Models 5 to 9 were
adjusted for transplant center volume. Models 1 to 4 were in-
ternally validated by bootstrap, and models 5 to 9 were tested
in the external validation set. The final simplified comprehen-
sive model (model 9) was selected for a low number of data
entries (17) and the highest C statistics in both data sets. All
modeling, data, and statistical analyses were conducted using
SPSS, version 25.0 (IBM SPSS) and Stata, version 14.0 (Stata-
Corp).
Results
The initial assessment included 1740 consecutive patients from
the Italian database, and 131 patients were excluded (Figure 1).
Thus, the derivation set included 1609 patients from this set
(Table 1). The external validation set included 538 patients who
underwent transplants at 2 UK centers. Figure 1 illustrates pa-
tient flow in both data sets. The characteristics of each data
set are shown in eTable 1 in the Supplement. On day 90, the
Figure 1. Patient Flow Diagram
2310 Consecutive cases, 2016-2017
570 Liver transplants from 
2 centersb
UK, external validation set
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Death at day 0 or 1
Unavailability of AST, bilirubin, or PLT
1651 Remaining cases 547 Remaining cases
1609 Remaining cases 538 Remaining cases
Available data for developing
and validating models
Available data for developing
and validating models
2147
Patients accrued in the derivation and external validation sets are displayed
separately. AST represents aspartate aminotransferase; PLT, platelet count.
a Included were 7 high-volume transplant centers and 7 intermediate-volume
centers. During the 11- to 90-day period, 1 patient in the derivation set was lost
to follow-up. During the 91- to 730-day period (24 months), 5 patients were
lost to follow-up.
b Included were 1 high-volume transplant center and 1 intermediate volume
center.
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Table 1. Study Population Characteristics in the Derivation Data Set After Exclusion of Patients
With Missing Data for the Parameters Used in the Modelsa
Characteristic No. (%) of patients Median (IQR)
Total No. of patients
included




Mean (SD) 61.9 (17.5) 65 (51.2-76.0) 1606 3 (0.2)
≥85 64 (4.0) NA 1606 3 (0.2)
Male sex (donor) 920 (57.2) NA 1609 0
Split 50 (3.1) NA 1609 0
DCDb 26 (1.6) NA 1609 0
MP graftsb 80 (5.0) NA 1609 0
Cold perfusion 60 (3.7) NA 1609 0
Normothermic perfusion 20 (1.2) NA 1609 0
Macrosteatosis (30% and higher) 38 (3.5) NA 1085 524 (32.6)
MP grafts 7 (12.1) NA 58
Non-MP grafts 31 (3.0) NA 1027
Recipient data
Age, mean (SD), y 55.5 (9.2) 57 (51-62) 1609 0
Male sex 345 (21.4) NA 1609 0
BMI
Mean (SD) 25.7 (4.0) 25.3
(23.0-28.1)
1596 13 (0.8)
<18.5 46 (2.9) NA 1596 13 (0.8)
>30 234 (14.7) NA 1596 13 (0.8)
Main indication NA 1607 2 (0.1)
HCV 643 (40.0) NA
HBV 230 (14.3) NA
Autoimmune hepatitis 31 (1.9) NA
Colestatic diseases 99 (6.2) NA
Alcoholic cirrhosis 355 (22.1) NA
Other indication 249 (15.5) NA
HCC (T2-T3) coindication 715 (44.4) NA 1609 0
Waiting time in HCC T2-T3, mo 5.5 (10.5) 1.9 (0.6-5.8) 715 0
MELD, mean (SD)
All patients 15.8 (8.3) 14.0 (9.0-19.9) 1609 0
HCC T2-T3 12.5 (6.4) 10 (8-15) 715 0
Cirrhosis and HCC T1 18.4 (8.7) 16 (12-23) 894 0
Grade 3-4 portal thrombosis
(Yerdel)
26 (1.6) NA 1609 0
Preoperative kidney support 24 (1.5) NA 1609 0
Preoperative lung support 12 (0.7) NA 1609 0
Packing for damage control 31 (1.9) NA 1609 0
VVBP 358 (22.2) NA 1609 0
Temporary portocaval
anastomosis
42 (2.6) NA 1609 0
CIT, min 420.1 (108.0) 418.5
(357.6-480.4)
1555 54 (3.4)
WIT, min 45.3 (22.1) 42.5
(26.0-60.0)
1327 282 (17.5)
Match and outcome data
D-MELD 965.5 (560.4) 825.5
(561.4-1236.6)
1606 3 (0.2)
Clavien-Dindo 3b or higher 330 (20.5) NA 1609 0
Length of stay, d
Hospital 22.6 (26.9) 26.0
(15.0-60.0)
1574 35 (2.2)
ICU 5.9 (9.9) 10.0 (3.0-24.0) 1555 54 (3.4)
Abbreviations: BMI, body mass index
(calculated as weight in kilograms
divided by height in meters squared);
CIT, cold ischemia time; DCD,
donation after cardiac death;
D-MELD, donor age × MELD; HBV,
hepatitis B virus; HCC, hepatocellular
carcinoma; HCV, hepatitis C virus;
ICU, intensive care unit; IQR,
interquartile range; MELD, Model for
End-stage Liver Disease; MP,
perfusion machine; NA, not
applicable; VVBP, venovenous
bypass; WIT, warm ischemia time.
a Missing data and their percentages
are also reported.
b Machine perfusion was used in 23 of
26 DCD grafts (88.5%) and in 57 of
1583 donations (3.6%) after brain
death grafts.
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incidence of EAF was 110 of 1609 patients (6.8%) in the deri-
vation set and 41 of 538 patients (7.6%) in the external valida-
tion set.
EASE Score and Probability Function
After preliminary Cox analysis (eFigure 1 in the Supplement),
several logistic models were developed. The final model esti-
mation of EAF at 90 days (model 9, EASE score) was identi-
fied (Figure 2A and B; eTable 2 and eTable 3 in the Supple-
ment). The EASE score was calculated using 17 data entries:
AST on PODs 1, 2, 3, 7, and 10; platelet counts on PODs 1, 3, 7,
and 10; bilirubin levels on PODs 1, 3, 7, and 10; MELD score;
PRBC transfusions at LT; THV; and transplant center volume.
The probability function was obtained by plotting the prob-
abilities of EAF at 90 days against the results of the logistic risk
function (Figure 3A). Five EAF risk classes were defined ac-
cording to the percentile distribution as in the original L-
GrAFT study20: class 1, extremely low risk (0-49.9 percen-
tile); class 2, low risk (50.0-89.9 percentile); class 3, moderate
risk (90.0-93.2 percentile); class 4, high risk (93.3-96.5 per-
centile); and class 5, extremely high risk (96.6-99.9). The line
between classes 4 and 5 represents the extremely high-risk
threshold (unsustainable risk cutoff). The risk curve at day 90
and the unsustainable risk cutoff are reported (Figure 3A).
The EASE score was derived as follows: EASE score = 0.958
+ (0.044 × MELD score at transplant) + (0.065 × PRBC) + (2.567
× thrombosis on days 1-10) + [0.000534 × AUC2 for ln (AST level)
on days 1, 2, 3, 7, and 10] + [−0.093 × AUC for ln (platelet count)
on days 1, 3, 7, and 10] + [−7.735 × slope for ln (platelet count) on
days 1, 3, 7, and 10] + (0.735 × slope for bilirubin level on days 1,
3, 7, and 10) + (−0.402 × high-volume center). The Hosmer-
Lemeshow goodness-of-fit statistic was 0.883.
Five representative cases from the study population are
described in eTable 4 in the Supplement. The EAF risk ranged
from 26% to 96% and depended on interactions among risk
factors, which could be detrimental or protective.
Kaplan-Meier Curves
The graft survival and patient survival curves are reported
in Figure 3B and C. The differences across the 5 EAF sur-
vival curves at 90 days were significant. Even though the
EASE score was designed to identify the EAF risk at 90 days,
its performance up to 48 months is also illustrated. After 24
months from transplant, the spread between patient and
graft curves increased for EASE class 4 and increased more
for EASE class 5. In class 5, the 48-month survival rate was
43.9% (95% CI, 30.2%-57.7%) for patients and 18.3% (95%
CI, 6.1%-28.1%) for grafts. Overall survival rates among
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A, B. The ROC curves for the Early
Allograft Failure Simplified Estimation
(EASE) score (final model 9) and
other models (5, 6, 7, and 8) at 90
days in the derivation set and in the
external validation set. C, The ROC
curves in the derivation set. D, The
ROC curves for the EASE score
developed at 90 days and applied at
30 days and for other estimated
scores in the derivation. D-MELD
indicates donor age × Model for
End-stage Liver Disease; DRI, Donor
Risk Index; EAD, Early Allograft
Dysfunction; L-GrAFT, Liver Graft
Assessment Following
Transplantation; MEAF, Model for
Early Allograft Function; and New
ET-DRI, New Eurotransplant Donor
Risk Index.
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patients were 95.2% (95% CI, 94.1%-96.2%) at 3 months,
88.7% (95% CI, 87.1%-89.9%) at 24 months, and 84.6%
(95% CI, 82.2%-87.1%) at 48 months. Graft hazard curves
and patient hazard curves are shown in eFigure 2 in the











































































































































































































































































































































































A, Sigmoidal day 90 early allograft
failure (EAF) distribution according to
the EASE score in 1609 evaluated
patients. Five different risk classes
are identified, with the dashed
central line denoting the threshold
for an unsustainable EAF risk. The
constant obtained by logistic
regression analysis was increased by
0.3060 to calibrate the
unsustainable risk cutoff at the 0
threshold. B and C, Early allograft
failure–free graft survival and patient
survival according to the 5 EASE
score risk classes are shown. The
dashed line between classes 4 and 5
in panel C representing the extremely
high-risk threshold (unsustainable
risk cutoff) indicates the poor survival
of patients in extremely high-risk
class 5. The extremely high-risk class
and the unsustainable risk cutoff
indicate the threshold that mandates
prompt retransplant.
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Supplement. The median (interquartile range) follow-up
was 36.4 (30.6-42.7) months.
Internal and External Validation
Comparisons of EASE with L-GrAFT,20 Model for Early Al-
lograft Function Scoring (MEAF),1 7 Early Allograft
Dysfunction,16 donor age × recipient biochemical Model for
End-stage Liver Disease (D-MELD),29 New Eurotransplant Do-
nor Risk Index (ET-DRI),30 and DRI6 are given in Table 2. In the
ROC curve analysis, the EASE score outperformed all of the
aforementioned scores without 95% CI overlap (C statistic,
0.87; 95% CI, 0.83-0.91; Figure 2C). The C statistic was inter-
nally validated through bootstrapping (eTable 5 in the
Supplement). We also tested the day 90 EASE model specifi-
cally in patients with or without hepatocellular carcinoma. The
C statistics were 0.88 (95% CI, 0.77-1.00) for patients with he-
patocellular carcinoma and 0.88 (95% CI, 0.73-0.94) for pa-
tients without hepatocellular carcinoma.
The EASE score was then validated on the external UK
database (C statistic, 0.78; 95% CI, 0.69-0.87) (Figure 2B).
The performance of the EASE score in the derivation set was
similar to that of models not including THV among the
covariates or excluding patients with THV, DCD, or MP in
various combinations. However, in the external validation
set, the EASE score including these variables outperformed
models 5 to 8.
Performance of EASE Score at Earlier Times
The C statistic of the EASE score was also calculated for PODs
15, 30, and 60. The EASE scores achieved even higher perfor-
mances than for POD 90 (Figure 2D; eFigure 3 in the Supple-
ment).
Number of Early Graft Losses and Estimate of Additional
Graft Requirements in Patients With Extremely High Risk
Among 54 grafts in patients at extremely high risk for EAF, 23
grafts were lost during the initial 10 PODs (6 deaths and 17 liver
retransplants). Of the remaining 31 grafts, 17 were lost during
the 11th to 90th POD, and only 14 survived 90 or more days.
Altogether, estimating that 50% to 75% of 18 grafts with dis-
mal prognosis on day 11 could be considered suitable for re-
transplant, the additional requirement would be 8.5 to 12.8
grafts in 2 years (ie, 0.5%-0.8% of total grafts).
Discussion
To our knowledge, this is the first large, multicenter, vali-
dated study to envisage the outcome of patients with EAF in
view of liver retransplant. The EASE score has been designed
to estimate EAF at 90 days and results from a logistic model
that includes 8 covariates. Four are kinetic variables obtained
during the first 10 days after LT. The remaining are MELD scores
at transplant, intraoperative PRBC transfusion requirement at
LT, occurrence of THV within 10 days, and transplant center
volume. The EASE score improves the day 90 estimation abil-
ity of other models, including Early Allograft Dysfunction,
MEAF, and L-GrAFT.16,17,20
The availability of risky grafts prompts the transplant com-
munity to pursue a new comprehensive definition of EAF. Fol-
lowing initial EAF definitions,1,2 the discrimination ability of
EAF estimation improved through multivariate models,3,5 lead-
ing to a binary early allograft dysfunction definition.16 Mod-
ern approaches exploit the dynamic changes in a few post-
transplant recipient parameters, resulting in a substantial
improvement in comparison with previous algorithms.17,20 In
particular, L-GrAFT captures 3 main aspects of graft damage
and recovery: cytolysis (in line with the historical definitions
of EAF), inability to sufficiently clear bilirubin, and endothe-
lial activation with platelet consumption.33,34 Adopting a simi-
lar approach, the EASE score simplifies and refines the L-
GrAFT, including additional variables expressing pretransplant
severity of liver disease (MELD), surgical complexity (PRBC),
and THV. On the basis of the literature, we used AST level in-
stead of alanine aminotransferase level,4,13,20,35,36 whereas the
international normalized ratio was not significant and there-
fore not entered into the final model. We selected the EASE
score among the 9 developed models for the high C statistic
in the derivation and validation sets. This model includes all
graft categories, encompassing different possible scenarios.
The EASE score addresses the unmet clinical need of iden-
tifying patients at the 10th POD for whom an early retrans-
plant is the sole option. Previous studies and clinical experi-
ence suggest better outcomes for liver retransplant when
performed earlier.23,24,37-39 Listing a patient for retransplant
is challenging.23,24,40,41 The decision depends on several is-
sues, which may change day by day. Indeed, a reluctance to
retransplant may exist in the absence of clear and immediate
signs of graft failure, delaying for several weeks the decision
to relist. Likewise, postponing retransplant leads to an increas-
ing number of patients who are finally unfit for retransplant
due to the development of medical complications (eg, kidney
failure, respiratory complications, sepsis, and multiple organ
failure) that preclude successful retransplant and definitely lead
to death. Moreover, the increased availability of DCD, stea-
totic, and MP organs makes crucial the reliable prediction of
the EAF risk.11,13,21
The EASE score clearly identifies patients on POD 10 with
a very high EAF risk, which is, indeed, unsustainable. The avail-
ability of a robust tool to timely estimate EAF is therefore highly
desirable to prevent clinicians from missing the window of op-
portunity for retransplant among their patients.
Including MELD, PRBC, and THV among the EAF deter-
minants undoubtedly represents a major difference from all
previous algorithms. Bilirubin level and international normal-
ized ratio in the pre-MELD era and, more recently, MELD it-
self have been associated with donor quality and have been
identified as cofactors of primary dysfunction or EAF.3,5,29,42-44
The MELD score estimates EAF in univariate analysis and, with
a lower odds ratio due to other competing factors, in multi-
variate analysis. The result is more evident in patients with-
out hepatocellular carcinoma with high MELD scores and se-
vere decompensation of liver function. The inclusion of PRBC
is innovative, too. We translated a well-known concept from
general surgery to transplant surgery: high PRBC consump-
tion reflects increased risk and poorer outcomes.45
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Table 2. Characteristics of EASE Score and Other Published Scoresa





2015 L-GrAFT,20 2018 EASE 2020




Graft recovery Graft recovery




Graft failure Graft failure Graft failure Comprehensive
graft failure
Cutoff ≥2 4 >1628/>1628 >2 ≥8 >1.3 >0
% Of estimated cases 80% at 90 d 75% at 180 d 84%/86% at 90 d 79% at 90 d 70% at 90 d 16% at 90 d 28% at 90 d
Day of evaluation in
relation to LT
Intraoperative 7 −1 Intraoperative 3 10 10
Donor
Age X X X
g-GT X

















Cold ischemia time X X
Rescue allocation X





INR >1.6 at day 7 X
Bilirubin >10 mg/dL at
day 7
X
ALT or AST >2000 U/L
at day 7
X
ALT maximum from day
1 to day 3
XXX
INR maximum from day
1 to day 3
XXX
Score bilirubin on day 3 XXX
AST from day 1 to day
10
XXXXXXXXXX
Bilirubin, daily from day
1 to day 10
XXXXXXXXXX
Platelets, daily from day
1 to day 10
XXXXXXXXXX
INR maximum from day
1 to day 10
XXXXXXXXXX
AST on days 1, 2, 3, 7,
and 10
XXXXX
Platelets on days 1, 3,
7, and 10
XXXX






No. of variables 8 3 2 8 3 4 7b
Total No. of
determinations
8 3 2 8 9 40 17
(continued)
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In the derivation set, models not including THV among the
covariates displayed negligible differences compared with the
EASE score. However, the EASE score outfit all other models
in the validation set. There are several reasons for consider-
ing THV as a potential EAF determinant. First, in the in-
cluded patients, the majority of thromboses occurred during
the first 72 hours, and it is difficult to decipher to what extent
cytolysis depended on ischemia-reperfusion injury or to THV-
associated ischemic damage. Ischemia-reperfusion injury may
act as a cofactor of concurrent vascular problems, and the im-
pact of arterial thrombosis may range from minimal to se-
vere, whereas isolated portal thrombosis is generally better tol-
erated. Evidence from other studies reports that up to 51% of
cases of hepatic artery thrombosis respond to prompt revas-
cularization, fibrinolysis, or anticoagulation therapy without
resulting in graft failure.46,47 Moreover, our study population
included patients without THV on day 10 who later devel-
oped thrombosis as well as patients with THV who re-
sponded to revascularization and to fibrinolysis/anticoagula-
tion therapy. Conversely, moderate parenchymal dysfunction
may be worsened by additional thrombotic events. In univari-
ate analysis, either arterial or portal thrombosis significantly
estimated EAF, with a higher odds ratio for arterial than por-
tal thrombosis. Nevertheless, in multivariate analysis, a sig-
nificant risk for EAF was detected only when arterial and por-
tal thrombosis cases were combined. Notably, we failed to show
a predictive role for donor age or for DCD or MP grafts. Al-
though all these factors might lead to graft loss in a minority
of cases,13,14 higher graft failure rate has been reported later
than 90 days owing to ischemic cholangiopathy. We also failed
to show that donor macrovesicular steatosis may be associ-
ated with detrimental effects. This failure may be due to the
presence of competing recipient variables, such as AST or bil-
irubin levels.
Finally, liver retransplant remains the only available treat-
ment of EAF due to either parenchymal or vascular causes. Dif-
ferent from previous scores, the EASE score includes almost
all components of the process leading to graft failure, and we
believe that this characteristic might explain a better perfor-
mance of the EASE score compared with less multifaceted
scores. We also tested the EASE score on PODs 15, 30, and 60,
obtaining better C statistic results compared with 90 days. We
suppose that the estimation ability of EASE slightly de-
creases with the increase of the incidence and severity of in-
fections. Septic events are not considered by this score. Even
though preoperative sepsis, high lactate levels, and high se-
quential organ failure assessment scores at intensive care unit
admission are well-known predictors of graft failure and
futility,48,49 in the posttransplant period, sepsis generally oc-
curs after POD 10, when EASE is calculated. However, the ex-
cellent C statistic on POD 15 supports the prompt referral to
retransplant of few controversial high-risk cases, with negli-
gible harm to the waiting list.50
The EASE score enables the rating of the EAF risk in a
range from 0% to 100%. It can be helpful to evaluate the
efficacy of standard, DCD, or MP grafts in critical appraisal
of single-center or multicenter analyses. The information
provided by the EASE score, particularly in the 2 upper EAF
risk classes, might also be useful to weigh the retransplant
risks against contraindications for relisting. The EASE
model performs best as a continuous score. However, for
practical reasons, we identified the boundary between class
4 and class 5 as the unsustainable threshold for EAF risk
(EASE score >0).
In addition, the EASE score enables the stratification of pa-
tient survival up to 4 years. The 48-month patient survival rate
of EASE class 5 is 44%, and we could hypothesize an ex-
pected 5-year survival rate slightly higher than 40%. In other
words, although late retransplant can rescue some grafts lost
for sequalae of ischemic cholangiopathy, patient survival still
remains below the futility threshold of 50% at 5 years.25,29,51,52
Considering that late retransplant is a demanding and chal-
lenging procedure, the EASE risk calculation on day 10 may al-
low for an early and efficacious retransplant indication, re-
ducing the need for late retransplant due to ischemic
cholangiopathy.
Table 2. Characteristics of EASE Score and Other Published Scoresa (continued)





2015 L-GrAFT,20 2018 EASE 2020
Discrimination ability
at 90 d
In the derivation set Not reported 0.72c 0.70 and 0.64 0.63 Not reported 0.85 0.87
In the validation set or
external data setd
0.57d 0.6331,c,d 0.72 and 0.64 0.5831,d 0.7332,d 0.71e 0.78
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
DCD, donation after cardiac death; D-MELD, donor age × Model for End-stage
Liver Disease; DRI, Donor Risk Index; EAD, Early Allograft Dysfunction; EASE,
Early Allograft Failure Simplified Estimation; g-GT, gamma-glutamyl
transpeptidase; L-GrAFT, Liver Graft Assessment Following Transplantation;
INR, international normalized ratio; LT, liver transplant; MEAF, Model for Early
Allograft Function; MELD, Model for End-stage Liver Disease; New ET-DRI, New
Eurotransplant Donor Risk Index.
SI conversion factors: To convert bilirubin to μmol/L, multiply by 17.104; ALT and
AST to μkat/L, by 0.0167
a Scores are different in terms of object, end point, cutoff, number of factors
used and total number of entries as well as the discrimination ability at 90
days. The L-GraFT and EASE scores presented the highest C statistic (0.85 and
0.87, respectively). However, the number of data entries necessary to
calculate is 17 for EASE and 40 for L-GrAFT. X indicates the characteristics
included in the score, multiple X’s indicate data collected at multiple days, and
number of X’s indicates the number of days.
b The number of variables is 7; however, the number of factors included in the
model is 8 because the platelet count is included as the area under the curve
and as slope.
c At 180 days.
d External data set.
e In Figure 2C and eTable 5 of the Supplement.
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The main strength of EASE is the great estimation of fail-
ure at 90 days, already calculated shortly after the first week
of transplant, which is better than any other model. Second-
ary strengths are the large number of transplants, the solid sta-
tistical method, and the recent observational period (2016-
2017). Moreover, the EASE score was developed using a
multicenter design and was subjected to 2 types of validation
(internal, compared with other models by ROC bootstrap-
ping; and external, using data from 2 UK centers). Further-
more, the present study introduces the innovative concept of
the unsustainability of extremely high-risk situations, sug-
gesting for them listing for prompt retransplant. Although it
evolved from L-GrAFT, EASE requires fewer data entries and
appears more user friendly in clinical practice.
Limitations
Our study is not free from limitations. First, the data sets in-
clude retrospective series of liver transplants across Italy and the
UK, and the proposed algorithm cannot straightaway be ex-
tended to countries with potential differences in donor and re-
cipient characteristics. Second, owing to the exclusion of some
recipient categories (ie, acute liver failure; patients with HIV; pa-
tients with combined grafts; and both domino and living graft
recipients), the EASE score might not apply to these recipients.
Third, the EASE score is not useful to guide the indication to re-
transplant during the first 10 days because it is calculated on POD
10. For the first 10 days, additional tools are needed. Moreover,
the number of PRBC units transfused and the management of
vascular thrombosis may depend on transplant center policies
and anesthesiology regimens.53,54 Finally, our study was not ex-
tended to low-volume centers, and the application of the EASE
score in this setting needs to be verified.
Conclusions
Refining the L-GrAFT algorithm, we increased the ability to es-
timate EAF through an EASE score, a new simplified compre-
hensive model. The EASE score will support transplant sur-
geons and hepatologists in the decision-making process of
listing patients for retransplant. EASE represents a valuable tool
to quantify early graft function, and the highest-risk class may
serve as an end point in future trials. Further national and in-
ternational studies are warranted.
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